AOD 9604 5mg Vial | Futureproof Peptides

AOD 9604 5mg Vial

Product Overview

AOD 9604 5mg Vial is the supplied product name for a vial presentation containing a stated quantity of 5mg of AOD-9604. The product name identifies Futureproof Peptides as the brand, although the brand and product specifications have not been independently verified. AOD-9604 is a synthetic peptide fragment related to human growth hormone and has been investigated in scientific research. This page provides factual product information, not a claim of medical effectiveness or suitability for human use.

What is AOD-9604?

AOD-9604 is a synthetic 16-amino-acid peptide. According to the US Food and Drug Administration (FDA), it is based on amino acids 177–191 of human growth hormone, with an additional tyrosine at the N-terminal end. It is therefore more accurately described as a growth-hormone C-terminal fragment analogue than as a complete growth hormone.

AOD-9604 has been investigated in preclinical research and was also studied during historical clinical development for obesity. That history does not establish that the compound is an effective or approved weight-management medicine. A 2004 review indexed on PubMed describes its earlier development programme, including Phase IIa studies.

Product presentation

The supplied name specifies a 5mg vial. This identifies the stated quantity and container format, but does not confirm the chemical form, formulation, concentration, excipients, purity, sterility or physical condition of the contents.

The FDA distinguishes between AOD-9604 free base and AOD-9604 acetate, noting that these are different bulk drug substances. The product name supplied here does not say which form is present. That distinction should be confirmed from an authenticated product specification before the listing is published.

Research background and evidence

AOD-9604 has been studied in relation to metabolic research and its proposed biological activity. Early research and development explored its potential in obesity, but the existence of research studies does not establish a reliable or clinically meaningful effect in people.

The FDA’s 2024 briefing document reviewed available information on AOD-9604 free base and AOD-9604 acetate. It discussed limitations in the characterisation of the substances and concerns relevant to peptide impurities, aggregation, immunogenic potential and the challenges of adequately characterising peptide materials. The FDA document also summarised historical clinical findings, including studies that did not demonstrate statistically significant weight loss compared with placebo. This is important context when evaluating claims made about the compound.

For readers who want to explore the published scientific background, the PubMed review, “AOD-9604 Metabolic” provides a record of its earlier development history. The FDA’s 2024 briefing document provides further detail about substance characterisation, historical research and the agency’s safety considerations.

Quality, documentation and transparency

No batch-specific Certificate of Analysis, independent laboratory report, purity result, sterility report, manufacturer specification or traceability record has been supplied for this vial. It would therefore be inaccurate to describe it as independently tested, sterile, pharmaceutical grade, GMP certified or verified to a particular purity.

Before publishing the product, confirm the exact chemical form, stated quantity, manufacturer identity, batch information, expiry details and any available analytical documentation. If a Certificate of Analysis is supplied, it should correspond to the actual batch being listed. Generic certificates or documents relating to a different batch should not be presented as evidence for this vial.

Buying with confidence and UK regulatory context

Customers evaluating research materials should be able to distinguish confirmed specifications from unverified supplier claims. Product identity, chemical form, batch traceability, supporting documentation and clear intended-use information are important details to establish before relying on a listing.

In the UK, a “research use only” statement does not automatically determine a product’s legal status. The MHRA considers the substance, its properties, intended purpose and the way it is presented, including website wording and promotional claims. Its guidance on borderline products explains these factors. The MHRA also states that unlicensed medicines cannot be advertised to the public as medicines; see Advertise your medicines.

Important research-use notice

This page is factual information about the named compound and stated vial quantity. It does not establish that the product is authorised for human or veterinary use, nor does it provide a recommendation for administration or treatment. The product’s intended purpose and legal status must be confirmed before it is marketed or supplied in the UK.